Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced a strategic Research and Development Agreement with Amsterdam UMC and Eindhoven University of Technology to develop and ...
Our goal has always been to supply medical professionals with the tools they need to achieve exceptional results.”— ...
The new product offering will supply global life science researchers with performance and reliability in multi-fragment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results